Board of Directors

Mauro Severino Ajani

Non-Executive Director, Chairman


Italian (born 1955), founder and Board Member of Cosmo Pharmaceuticals since 2006 and main shareholder of Cosmo Holding S.a.r.l. (and thus indirectly of Cosmo Pharmaceuticals NV).
CEO of Cosmo Pharmaceuticals from 2006 to 2014. Sole Director of Cosmo S.p.A. from 1998 to February 2001.
From 1994 to 1996, he was the general manager of the Russian company Italcenter and took part in a joint venture of Italian and Russian entrepreneurs for the creation of a pharmaceutical product distribution company. He was a consultant of Pharmhispania from 1991 to 1993, an Italian-Spanish joint venture for the import/export and distribution of pharmaceutical products between Spain and Italy. In the period from 1983 to 1993, he was the marketing manager of Pharmajani S.r.l., a company engaged in the commercial distribution and logistics of pharmaceutical products. From 1980 to 1983, he was Nielsen’s area manager for over-the-counter products of the Serono OTC company while in the period from 1978 to 1980 he worked as a salesman for the Lepetit company and for the Gazzoni company in the OTC sector.

Alessandro Della Chà

Executive Director, CEO


Italian (born 1963), has been a Board Member of Cosmo Pharmaceuticals NV since 2006 and is the CEO as of 27 March 2014.

Until 27 March 2014, he was senior partner at Studio Legale Edoardo Ricci e Associati, Milan, where he specialized in company law, mergers and acquisitions. He joined the firm in 1988. From 1987 to 1988 he was assistant of the central director for corporate matters at Fininvest Group. From 1994 to 1998 he was director of II.PP.A.B. Milan (formerly ECA), a charitable institution owning hospitals and specialized in elderly care.

Alessandro Della Chà has a degree in law from the University of Milan, Italy, and an LL.M. in European Union commercial law from the University of Leicester, United Kingdom. He is a lecturer in conferences and seminars held by universities and institutions on commercial and company law issues.

Hans Christoph Tanner

Executive Director, Head of Transactions Office and
Head of Investor Relations


Swiss (born 1951), has been a Board Member of Cosmo Pharmaceuticals NV since 2006. Since 2006 until May 2016 he was Chief Financial Officer and Head of Investor Relations of Cosmo Pharmaceuticals, from May 2016 he has been Head of Transactions Office and Head of Investor Relations.

Chris Tanner has a diploma as an economist and a PhD in economics from the University of St.Gallen. He joined UBS in 1977 and following a management trainee program worked in various foreign assignments. In 1985, he became a member of the global credit committee and from 1987 to 1992 was the head of corporate banking in Asia, Australia and Africa as well as Southern Europe. In 1992 he became head of corporate finance and capital markets at UBS in Zurich. In 1998, one year after UBS’s merger with SBC, he left to become a partner of Dr. Ernst Müller-Möhl, cofounded the “20 Minuten” group of newspapers and founded A&A Active Investor, a listed investment company. From 2002 – 2006 he was a corporate finance adviser and participated in numerous fund raisings amongst other for the private placement of Cosmo Holding S.p.A.

He is a board member and head of the audit committee of DKSH AG (SIX: DKSH), a market expansion company, a board member and head of the Compensation Committee of Private Equity Holding AG, (SIX: PEH) a private equity investment company, Joimax GmbH, a medtech company, and Qvanteq AG, a medtech start-up company.

None of the companies that Chris Tanner is a major shareholder of has any business activities with the Company.

Dieter A. Enkelmann

Non-Executive Director


Swiss (born 1959), has been a Board Member of the Cosmo Pharmaceuticals NV since 2006.

Dieter A. Enkelmann is Chief Financial Officer and member of the executive management board of Julius Baer Group Ltd., the largest independent private banking group in Switzerland, listed on the SIX Swiss Exchange. From 2003 to 2006 he was Chief Financial Officer of Barry Callebaut AG, the world’s leading manufacturer of high-quality cocoa, chocolate and confectionary products, which is listed on the SIX Swiss Exchange. From 1997 to 2003 he was at Swiss Re as head of finance of the business unit financial services and as head of corporate finance, treasury, and investor relations. From 1985 to 1997 he held several positions at Credit Suisse, both in Zurich and London. Dieter A. Enkelmann was a board member of iNNutriGEL AG, in Schlieren, Switzerland, and was member of the board and head of the compensation committee of SIX-listed GAM Holding Ltd., in Zurich, Switzerland. Julius Baer bank provides no services for the Company.

He graduated from the University of Zurich, where he obtained a degree in law.

Maria Grazia Roncarolo

Non-Executive Director


Italian (born 1954), has been a Board Member at Cosmo Pharmaceuticals NV since April 2012.

Dr. Maria Grazia Roncarolo is Professor of Pediatrics at Stanford University, California, USA, and Codirector of the Stanford Institute for Stem Cell Biology and Regenerative Medicine as of 1 June 2014 and Professor of Pediatrics, School of Medicine and Surgery, San Raffaele Vita-Salute University, in Milan. From 2008 to 2013 she was the Scientific Director of the San Raffaele Scientific Institute in Milan. From 2000 to 2007 she was the Director of the San Raffaele Telethon Institute for Gene Therapy. Prior to joining San Raffaele, she was a scientific staff member of the DNAX Research Institute of Molecular and Cellular Biology, Palo Alto, USA.

Dr. Maria Grazia Roncarolo studied medicine and has a PhD from the University of Torino. She has extensive experience in immunological research focusing on the mechanism of tolerance in patients transplanted with hematopoietic stem cells and spent more than 8 years at the DNAX Research Institute of Molecular and Cellular Biology, Human Immunology Department, in PaloAlto, California, USA, researching on the basic biology of hematopoietic stem cells, cytokines and cytokine receptors discovery and biology, and immunological tolerance.

Dr. Roncarolo has actively collaborated to the development of research programs for industry and biotechnology companies, having served as member of Schering Plough’s “Cytokine Team” (1993–1996), as a founding member of the scientific advisory board for Kinetix Pharmaceutical (1997–2000), and as Consultant for Novartis Pharmaceutical in the areas of immunology, transplantation and gene transfer (1997–2002).

In 2000, Maria Grazia Roncarolo was awarded the honor of Ufficiale dell’Ordine “Al Merito della Repubblica Italiana” for scientific merits. In 2005 she was elected member of the Academia Europea of Sciences. Maria Grazia Roncarolo is among the most cited scientists according to (Thomson Reuters, Philadelphia). She is inventor of 14 international patents issued or pending.

Kevin Donovan

Non-Executive Director


Irish (born 1959), has been a board member of Cosmo Pharmaceuticals NV since March 2016.

Kevin Donovan is a Fellow of the Institute of Chartered Accountants in Ireland and a member of the Institute of Directors. Kevin Donovan graduated from University College Dublin with a Bachelor of Commerce Degree and worked with PWC in Dublin for four years before transferring to PWC in Boston for a further three years. He was a founding shareholder and director of Sentinel Investments, where he developed a substantial portfolio of international aircraft leasing business, before selling his interest in Sentinel in 2006.

Kevin Donovan has also been a partner in FGS Chartered Accountants in Dublin (now Grant Thornton) and has held a number of board positions with foreign corporations setting up operations in Ireland in a variety of industries including aviation, pharmaceuticals, biotechnology and oil exploration. He is currently active in international property investment and manages a substantial property portfolio in Berlin.

Eimear Cowhey

Non-Executive Director


Irish (born 1966), has been a board member of Cosmo Pharmaceuticals NV since May 2017.

Eimear Cowhey is a qualified Irish lawyer holding a Bachelor of Civil Law and a Certificate in Financial Services Law from University College Dublin, a Diploma in Accounting and Finance from the Association of Chartered Certified Accountants, a Diploma in Company Direction from the Institute of Directors and is in the course of achieving Chartered Director status from the Institute of Directors (London). Eimear Cowhey has over 25 years' experience in the offshore investment funds industry and for the last ten years has been a non-executive independent chairman and director of various investment fund and management companies in Dublin and Luxembourg.

From 1999 to 2006 Eimear Cowhey held various executive positions within The Pioneer Group, including Head of Legal and Compliance and Head of International Product Development. From 1992 to 1999 she held various executive positions within Invesco Asset Management, including Managing Director, Global Fund Director and Head Legal Counsel.

She is a former Council member and past Chairman of Irish Funds (the Irish investment fund industry association) and is a former member of the IFSC Funds Group a joint government/industry group to advise the Irish government of investment fund related matters. She is a founder and current Chair of basis.point which is the Irish investment fund industry charity focused on alleviating poverty through education, particularly among the youth of Ireland.

Delivered by Investis – link to website (opens in a new window)